2024-10-09 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, consumables, and services for research, analytical, diagnostic, and pharmaceutical applications.

**Performance Analysis:**

**1. Performance Comparison to S&P 500 (VOO):**

* TMO has outperformed the S&P 500 (VOO) significantly, with a cumulative return of 242.04% compared to VOO's 133.14%.
* The current divergence between the two is 108.9%, which represents a relative divergence of 50.35% based on historical data. This signifies that TMO has outperformed VOO by a substantial margin but is currently at the 50.35% percentile of its historical divergence range.

**2. Recent Price Action:**

* Closing price: 598.61
* 5-day moving average: 608.75
* 20-day moving average: 612.93
* 60-day moving average: 600.22

The price action shows a recent downward trend, as the closing price is below all three moving averages. However, the 60-day moving average suggests a possible support level around 600.22.

**3. Technical Indicators:**

* RSI: 39.59 (Below 50, suggesting oversold condition)
* PPO: -0.35 (Negative value, indicating bearish momentum)
* Delta_Previous_Relative_Divergence: -9.42 (Negative value, indicating short-term bearish trend)
* Expected Return: 11.29% (Potential 5-year expected return exceeding S&P 500 performance)

These indicators suggest that TMO is currently in a bearish trend, with the RSI pointing towards oversold conditions. However, the expected return remains positive, suggesting potential for future growth.

**4. Recent Earnings and Outlook:**

| Date      | EPS   | Revenue      |
|----------|-------|--------------|
| 2024-08-02 | 4.05  | 10.54 B$     |
| 2024-05-03 | 3.47  | 10.35 B$     |
| 2023-11-03 | 4.44  | 10.57 B$     |
| 2023-08-04 | 3.53  | 10.69 B$     |
| 2024-08-02 | 3.53  | 10.69 B$     |

The latest earnings report for Q2 2024 showed EPS of 4.05, exceeding analyst expectations. The company's revenue also grew slightly compared to the previous quarter. Overall, the recent earnings indicate continued strong performance and potential for growth.

**5. News and Recent Issues:**

* **Recent Market Outlook:** Thermo Fisher Scientific is expected to benefit from the continued growth in the global healthcare and life sciences industries.  The company's focus on innovation and expansion into emerging markets is expected to drive future growth.
* **Analyst Opinions:** Most analysts have a positive outlook on TMO, with a consensus rating of "Buy" or "Strong Buy."  Analysts highlight the company's strong market position, robust financial performance, and attractive growth prospects.
* **Performance Highlights:** TMO has consistently outperformed its industry peers and the broader market. The company's strong revenue growth and profitability have been driven by its focus on innovation and expansion into new markets. 

**6. Overall Analysis:**

Thermo Fisher Scientific (TMO) has shown remarkable long-term performance, significantly outperforming the S&P 500. Despite recent price weakness, technical indicators suggest oversold conditions with potential for a rebound. The company's strong earnings performance and positive analyst sentiment support the long-term growth outlook. However, investors should be aware of the current bearish trend and potential for further downside in the short-term. 

**7. Conclusion:**

TMO offers a compelling investment opportunity for investors seeking long-term growth and exposure to the healthcare and life sciences industries. While recent price action suggests a short-term bearish trend, the company's fundamentals remain strong, and the long-term outlook is positive. Investors may consider holding or accumulating shares at current levels, potentially capitalizing on the potential for a rebound in the future. 
